AERAS 422

Drug Profile

AERAS 422

Alternative Names: AERAS422

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aeras Global TB Vaccine Foundation
  • Developer Aeras
  • Class Antituberculars; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Tuberculosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Tuberculosis(In volunteers) in USA (Intradermal, Injection)
  • 29 Aug 2013 Aeras receives 5-year grant from Department for International Development in the United Kingdom for vaccine development in tuberculosis
  • 02 Oct 2012 Aeras Global TB Vaccine Foundation is now called Aeras
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top